EMA — authorised 21 June 2018
- Marketing authorisation holder: Gilead Sciences International Limited
- Status: approved
EMA authorised Biktarvy on 21 June 2018
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 21 June 2018.
Gilead Sciences International Limited holds the EU marketing authorisation.